<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02179515</url>
  </required_header>
  <id_info>
    <org_study_id>140142</org_study_id>
    <secondary_id>14-C-0142</secondary_id>
    <nct_id>NCT02179515</nct_id>
  </id_info>
  <brief_title>Safety and Tolerability of a Modified Vaccinia Ankara (MVA)-Based Vaccine Modified to Express Brachyury and T-cell Costimulatory Molecules (MVA-Brachyury-TRICOM)</brief_title>
  <official_title>An Open Label Phase I Study to Evaluate the Safety and Tolerability of a Modified Vaccinia Ankara (MVA) Based Vaccine Modified to Express Brachyury and T-Cell Costimulatory Molecules (MVA Brachyury-TRICOM)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Institutes of Health Clinical Center (CC)</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Background:&#xD;
&#xD;
      - This cancer vaccine was developed to help teach the body's immune system to attack and&#xD;
      destroy cancer cells. It teaches immune cells to target the Brachyury protein. This protein&#xD;
      is present in some tumor cells, and it can help tumor cells spread to other parts of the&#xD;
      body. Researchers want to see whether the new Brachyury protein vaccine can help treat people&#xD;
      with advanced carcinomas.&#xD;
&#xD;
      Objective:&#xD;
&#xD;
      - To test the safety and effectiveness of giving the modified vaccinia Ankara&#xD;
      (MVA)-brachyury-B7-1, ICAM-1 (Intercellular Adhesion Molecule 1), and LFA-3 (lymphocyte&#xD;
      function-associated antigen 3) TRICOM vaccine to people with cancer.&#xD;
&#xD;
      Eligibility:&#xD;
&#xD;
      - Adults ages 18 and over whose type of cancer has not responded to standard therapies who do&#xD;
      not have a history of autoimmune diseases and are capable of taking care of themselves.&#xD;
&#xD;
      Design:&#xD;
&#xD;
        -  Participants will be screened with a medical history and physical exam. They will have&#xD;
           blood and urine tests. They may have a computed tomography (CT) scan, a positron&#xD;
           emission tomography (PET) scan, and a brain magnetic resonance imaging (MRI) scan. They&#xD;
           may have a bone scan. They will have an electrocardiogram (ECG) to test heart rhythm.&#xD;
&#xD;
        -  Participants will have visits about every 4 weeks. They will have a physical exam and&#xD;
           blood and urine tests. They will be injected with the vaccine under the skin into the&#xD;
           upper thigh or around the armpits.&#xD;
&#xD;
        -  CT scans or MRI scans will be done at visit 1, after 3 months on study, and again 3&#xD;
           months later if still on the study. Another ECG will be done at their last vaccine&#xD;
           visit.&#xD;
&#xD;
        -  When participants stop the vaccine, they will return for visits until they recover from&#xD;
           any side effects. They will have tests including physical exam, blood tests, scans, and&#xD;
           x-rays.&#xD;
&#xD;
        -  Participants will be asked to enroll in another study for long-term follow-up.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Background:&#xD;
&#xD;
        -  modified vaccinia Ankara (MVA)-brachyury-B7-1, ICAM-1 (Intercellular Adhesion Molecule&#xD;
           1), and LFA-3 (lymphocyte function-associated antigen 3) TRICOM is a novel recombinant&#xD;
           vector-based therapeutic cancer vaccine designed to induce an enhanced immune response&#xD;
           against brachyury, which is overexpressed in many solid tumor types, such as lung,&#xD;
           breast, ovarian, chordoma, prostate, colorectal, and pancreatic adenocarcinoma.&#xD;
&#xD;
        -  Modified vaccinia Ankara (MVA) is a replication-deficient, attenuated derivative of&#xD;
           vaccinia. It is used in the smallpox vaccination and is now being developed as a&#xD;
           recombinant viral vector to produce vaccines against infectious diseases and cancer.&#xD;
&#xD;
        -  Many MVA vector-based trials conducted in patients with cancer have demonstrated its&#xD;
           safety and the immunogenicity of its transgenes.&#xD;
&#xD;
        -  Brachyury is a member of the T-box family of transcription factors. It is overexpressed&#xD;
           in cancer cells compared with normal tissue and has been linked to cancer cell&#xD;
           resistance and metastatic potential.&#xD;
&#xD;
        -  Brachyury as a vaccine target has been demonstrated to be safe in an ongoing phase I&#xD;
           study of recombinant yeast-brachyury and to generate brachyury-specific T-cell&#xD;
           responses.&#xD;
&#xD;
        -  Poxviral vaccines delivering a triad of three human T-cell costimulatory molecules&#xD;
           designated TRICOM (B7.1, ICAM-1 and LFA-3) have been extensively studied in both&#xD;
           preclinical and clinical studies and have demonstrated their ability to induce robust&#xD;
           T-cell activation and provide evidence of clinical benefit.&#xD;
&#xD;
        -  In vitro, MVA-brachyury-TRICOM is able to effectively expand brachyury-specific cluster&#xD;
           of differentiation 8 (CD8+) and cluster of differentiation 4 (CD4+) T cells from&#xD;
           peripheral blood mononuclear cells.&#xD;
&#xD;
        -  Previous work indicates that MVA-brachyury-TRICOM will induce activation a distinct&#xD;
           Tcell subpopulation from that seen with yeast-brachyury vaccine already in development.&#xD;
&#xD;
      Objectives:&#xD;
&#xD;
      To determine the safety and tolerability of escalating doses of MVA-brachyury-TRICOM vaccine.&#xD;
&#xD;
      Eligibility:&#xD;
&#xD;
        -  Patients must have histologically confirmed malignancy that is metastatic or&#xD;
           unresectable locally advanced malignant solid tumor. In the case of chordoma,&#xD;
           unresectable, locally recurrent, or metastatic tumors are acceptable for enrollment,&#xD;
           given that this represents incurable disease. As much as possible, patients enrolled&#xD;
           will have tumor types with known increased expression of brachyury (such as lung,&#xD;
           breast, ovarian, prostate, colorectal, pancreatic, or chordoma).&#xD;
&#xD;
        -  Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 1 at study entry&#xD;
&#xD;
        -  Age greater than or equal to 18 years.&#xD;
&#xD;
        -  Prior Therapy: Completed, or disease progression on at least one prior line of disease&#xD;
           appropriate therapy for metastatic disease, or not a candidate for therapy of proven&#xD;
           efficacy for their disease.&#xD;
&#xD;
      Design:&#xD;
&#xD;
        -  This is an open-label, phase I trial with sequential cohorts of patients (3-6 patients&#xD;
           per dose cohort) with dose escalation of MVA-brachyury-TRICOM vaccine.&#xD;
&#xD;
        -  Three cohorts will receive MVA-brachyury-TRICOM vaccine administered subcutaneously as&#xD;
           either 1, 2, or 4 injections of study drug (1 injection equal to 2 x 10^8 infectious&#xD;
           units at monthly (28 days +/- 4 days) intervals for 3 months (treatment).&#xD;
&#xD;
        -  Expansion cohorts of up to 10 patients may be enrolled at the two highest tolerated dose&#xD;
           levels. These cohorts will allow certain standard, relatively non-toxic therapies to&#xD;
           continue while patients receive vaccine.&#xD;
&#xD;
        -  Up to 18 patients may be required to be enrolled in the 3 cohorts, plus an additional 10&#xD;
           at the maximum tolerated dose (MTD) and at the dose level just below it. Thus, up to 38&#xD;
           patients may be theoretically required to complete this trial. If 3 patients per month&#xD;
           can be accrued, the study is expected to require 1 year to complete the necessary&#xD;
           enrollment.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">June 28, 2014</start_date>
  <completion_date type="Actual">February 28, 2018</completion_date>
  <primary_completion_date type="Actual">April 6, 2017</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants With Serious and Non-serious Adverse Events Assessed by the Common Terminology Criteria for Adverse Events (CTCAE v4.0)</measure>
    <time_frame>Date treatment consent signed to date off study, approximately 9 months and 6 days for DL1, 17 months and 3 days for DL2, and 23 months and 13 days for DL3.</time_frame>
    <description>Here is the count of participants with serious and non-serious adverse events assessed by the Common Terminology Criteria for Adverse Events (CTCAE v4.0). A non-serious adverse event is any untoward medical occurrence. A serious adverse event is an adverse event or suspected adverse reaction that results in death, a life-threatening adverse drug experience, hospitalization, disruption of the ability to conduct normal life functions, congenital anomaly/birth defect or important medical events that jeopardize the patient or subject and may require medical or surgical intervention to prevent one of the previous outcomes mentioned.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants With Dose-Limiting Toxicities (DLT)</measure>
    <time_frame>28 days following the first injection of vaccine.</time_frame>
    <description>Dose-limiting toxicity (DLT) will be defined as any one of the following: Any grade ≥ 3 hematologic toxicity or grade ≥ 3 non-hematologic toxicity that is possibly, probably, or definitely related to study drug, except transient (≤ 48 hour) grade 3 fatigue, local reactions, flu-like symptoms, fever, headache, and laboratory abnormalities that are not associated with organ pathology. Also any ≥ grade 2 allergic and ≥ grade 2 autoimmune reaction(s) (except endocrine-related immune toxicity) will be defined as a DLT. Any grade 3 autoimmune endocrine-related toxicity that has not resolved clinically within 7 days of initiating therapy will also be defined as a DLT. Generalized erythroderma or macular or papular rash lasting less than 7 days and not associated with desquamation will not be DLTs.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Maximum Tolerated Dose (MTD)</measure>
    <time_frame>First 28 days of treatment.</time_frame>
    <description>The MTD will be the dose level at which no greater than 1/6 patients have a dose-limiting toxicity (DLT), and the next higher dose level has at least 2 patients with a DLT.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants With Grade 3 or Greater Adverse Events Possibly Related to Vaccine</measure>
    <time_frame>Date treatment consent signed to date off study, approximately 9 months and 6 days for DL1, 17 months and 3 days for DL2, and 23 months and 13 days for DL3.</time_frame>
    <description>Number of participants with Grade 3 or greater adverse events possibly related to vaccine assessed by the Common Terminology Criteria for Adverse Events (CTCAE v4.0). Grade 3 is severe or medically significant but not immediately life-threatening. Grade 4 is life threatening consequences, and Grade 5 is death related to adverse event.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Brachyury-Specific T-cell Responses Developed After 1, 2, and 3 Vaccinations</measure>
    <time_frame>Baseline (pre-vaccination), approximately day 29 (after 1 vaccination), approximately day 57 (after 2 vaccinations), and approximately day 85 (after 3 vaccinations)</time_frame>
    <description>A fluorescence activated cell sorting (FACS)-based assay for cluster of differentiation 4 (CD4) or cluster of differentiation 8 (CD8) T-cells expressing the cytokines interferon (IFN) gamma, interleukin 2 (IL2), and tumor necrosis factor (TNF) alpha, and/or cluster of differentiation 107a (CD107a) (a marker for lytic potential) was used to determine the numbers of participants showing development or enhancement of the level of brachyury-specific T-cells after vaccination.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Total Peripheral Blood Mononuclear Cells (PBMCs) in Peripheral Blood Before Vaccination, and After 1 and 3 Vaccinations</measure>
    <time_frame>Pre (Baseline), and approximately D29 (Post 1 vaccination) and D85 (post 3 vaccinations)</time_frame>
    <description>Blood samples collected were analyzed by multicolor flow cytometry in PBMCs for cluster of differentiation 4 (CD4), cluster of differentiation 8 (CD8), Natural Killer (NK), Natural Killer T (NKT), conventional dendritic cell (cDC), plasmacytoid dendritic cell (pDC), myeloid-derived suppressor cell (MDSC) and Tregs. Changes in levels PBMC subsets was a descriptive result with median and interquartile range reported. No formal statistical analysis by dose level was performed given the small sample size.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Positive Anti-Brachyury Antibodies</measure>
    <time_frame>Pre (Baseline), and approximately D29 (Post 1 vaccination), D57 (post 2 vaccinations) and D85 (post 3 vaccinations)</time_frame>
    <description>A positive brachyury antibody titer consisted of an absorbance to brachyury protein that was twice that obtained with the negative control protein Bovine serum albumin (BSA). A positive titer after vaccination may be indicative of an immune response to the vaccine.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in Serum Cytokines Soluble CD27 (sCD27) and Soluble Factors</measure>
    <time_frame>Pre (Baseline), and approximately D29 (Post 1 vaccination), and D85 (post 3 vaccinations)</time_frame>
    <description>Serum levels of Soluble CD27 (sCD27) were determined by enzyme-linked immunosorbent assay (ELISA) pre and post vaccination. Changes in levels of serum cytokines and soluble factors was a descriptive result with median and interquartile range reported. No formal statistical analysis by dose level was performed given the small sample size.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in Serum Cytokines Soluble CD40 Ligand (sCD40L) and Soluble Factors</measure>
    <time_frame>Pre (Baseline), and approximately D29 (Post 1 vaccination), and D85 (post 3 vaccinations)</time_frame>
    <description>Serum levels of sCD40L, were determined by enzyme-linked immunosorbent assay (ELISA) pre and post vaccination. Changes in levels of serum cytokines and soluble factors was a descriptive result with median and interquartile range reported. No formal statistical analysis by dose level was performed given the small sample size.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in the Ratio of Serums Soluble CD27 (sCD27):Soluble CD40 Ligand (sCD40L)</measure>
    <time_frame>Pre (Baseline), and approximately D29 (Post 1 vaccination), and D85 (post 3 vaccinations)</time_frame>
    <description>Serum levels of sCD27, sCD40L, and the ratio of sCD27:sCD40L were determined by enzyme-linked immunosorbent assay (ELISA) pre and post vaccination. Changes in levels of serum cytokines and soluble factors was a descriptive result with median and interquartile range reported. No formal statistical analysis by dose level was performed given the small sample size.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in Serum Cytokines Interleukin 2 (IL2), Interleukin 4 (IL4), Interleukin 10 (IL10), and Interferon Gamma (IFNg)</measure>
    <time_frame>Pre (Baseline), and approximately D29 (Post 1 vaccination), and D85 (post 3 vaccinations)</time_frame>
    <description>Serum levels of IL-2, IL-4, IL-10, and IFNg were determined by enzyme-linked immunosorbent assay (ELISA) pre and post vaccination. Changes in levels of serum cytokines and soluble factors was a descriptive result with median and interquartile range reported. No formal statistical analysis by dose level was performed given the small sample size.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Correlation of Brachyury Expression in Tissue Samples With Clinical Outcomes.</measure>
    <time_frame>2 -3 years</time_frame>
    <description>Correlation of brachyury expression in tissue samples with clinical outcomes.</description>
  </other_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">38</enrollment>
  <condition>Lung Cancer</condition>
  <condition>Breast Cancer</condition>
  <condition>Prostate Cancer</condition>
  <condition>Tumors (Others)</condition>
  <condition>Ovarian Cancer</condition>
  <arm_group>
    <arm_group_label>modified vaccinia Ankara (MVA)-brachyury-TRICOM vaccine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Three cohorts will receive modified vaccinia Ankara (MVA)-brachyury-B7-1, ICAM-1 (Intercellular Adhesion Molecule 1), and LFA-3 (lymphocyte function-associated antigen 3) TRICOM vaccine administered subcutaneously as either 1, 2, or 4 injections of study drug at monthly (28 days +/4 days) intervals for 3 months. Patients with stable disease may continue to receive vaccine for up to 6 monthly doses.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>MVA-brachyury- TRICOM</intervention_name>
    <description>It is an active cancer immunotherapy administered via subcutaneous injection.</description>
    <arm_group_label>modified vaccinia Ankara (MVA)-brachyury-TRICOM vaccine</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        -  INCLUSION CRITERIA:&#xD;
&#xD;
        (All Subjects)&#xD;
&#xD;
          1. Patients must have a metastatic or unresectable locally advanced malignant solid&#xD;
             tumor, histologically confirmed by the Laboratory of Pathology, National Cancer&#xD;
             Institute (NCI). In the case of chordoma, unresectable, locally recurrent, or&#xD;
             metastatic tumors are acceptable for enrollment, given that this represents incurable&#xD;
             disease. Efforts will be made, as much as possible, to enroll patients with tumor&#xD;
             types with known increased expression of brachyury (such as lung, breast, ovarian,&#xD;
             prostate, colorectal, pancreatic, or chordoma; other tumors may be included as data on&#xD;
             the level of brachyury in those tumors becomes available).&#xD;
&#xD;
          2. Patients may have measurable or nonmeasurable but evaluable disease. Patients with&#xD;
             surgically resected metastatic disease at high risk of relapse are also eligible.&#xD;
&#xD;
          3. Prior therapy: Patients must have completed or had disease progression on at least one&#xD;
             prior line of disease-appropriate therapy for metastatic disease, or not be candidates&#xD;
             for therapy of proven efficacy for their disease.&#xD;
&#xD;
          4. There should be a minimum of 4 weeks from any prior chemotherapy, immunotherapy and/or&#xD;
             radiation, with the exception of hormonal therapy for prostate and breast cancers,&#xD;
             human epidermal growth factor receptor 2 (HER2)-directed therapy for HER2+ breast&#xD;
             cancer (3+ immunohistochemistry (IHC) or fluorescence in situ hybridization (FISH+),&#xD;
             and erlotinib in epidermal growth factor receptor (EGFR)-mutated lung cancer in the&#xD;
             expansion cohort as detailed in section. There should be a minimum of 6 weeks from any&#xD;
             prior antibody therapies, (such as ipilimumab or anti-Programmed cell death protein 1&#xD;
             (PD1)/Programmed death-ligand 1 (PDL1) due to prolonged half-life.&#xD;
&#xD;
          5. Patients must have recovered (grade 1 or baseline) from any clinically significant&#xD;
             toxicity associated with prior therapy. Typically, this is 3-4 weeks for patients who&#xD;
             most recently received cytotoxic therapy, except for the nitrosoureas and mitomycin C,&#xD;
             for which 6 weeks is needed for recovery.&#xD;
&#xD;
          6. Age greater than or equal to 18 years. Because no dosing or adverse event data are&#xD;
             currently available on the use of modified vaccinia Ankara (MVA)-brachyury-B7-1,&#xD;
             ICAM-1 (Intercellular Adhesion Molecule 1), and LFA-3 (lymphocyte function-associated&#xD;
             antigen 3) TRICOM vaccine in patients &lt; 18 years of age, children are excluded from&#xD;
             this study but will be eligible for future pediatric trials.&#xD;
&#xD;
          7. Eastern Cooperative Oncology Group (ECOG) performance status less than or equal to 1&#xD;
             (Karnofsky greater than or equal to 70%).&#xD;
&#xD;
          8. Patients must have normal organ and marrow function as defined below:&#xD;
&#xD;
               -  Serum creatinine less than or equal to 1.5 x upper limit of normal OR creatinine&#xD;
                  clearance on a 24-h urine collection of greater than or equal to 50 mL/min.&#xD;
&#xD;
               -  Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) less than or&#xD;
                  equal to 3 x the upper limits of normal.&#xD;
&#xD;
               -  Total bilirubin less than or equal to 1.5 x upper limit of normal OR in patients&#xD;
                  with Gilbert's syndrome, a total bilirubin less than or equal to 3.0.&#xD;
&#xD;
               -  Hematological eligibility parameters (within 16 days of starting therapy):&#xD;
&#xD;
                    -  Granulocyte count greater than or equal to 1,500/mm^3&#xD;
&#xD;
                    -  Platelet count greater than or equal to 100,000/mm^3&#xD;
&#xD;
          9. Patients must have baseline pulse oximetry &gt; 90% on room air.&#xD;
&#xD;
         10. The effects of MVA-brachyury-TRICOM on the developing human fetus are unknown. For&#xD;
             this reason, women of child-bearing potential and men must agree to use adequate&#xD;
             contraception (hormonal or barrier method of birth control; abstinence) prior to study&#xD;
             entry and for the duration of study participation and for a period of 4 months after&#xD;
             the last vaccination therapy. Should a woman become pregnant or suspect she is&#xD;
             pregnant while she or her partner is participating in this study, she should inform&#xD;
             her treating physician immediately.&#xD;
&#xD;
         11. Patients with prostate cancer must continue to receive gonadotropin releasing hormone&#xD;
             (GnRH) agonist therapy (unless orchiectomy has been done). If a patient has refused&#xD;
             GnRH therapy, they may be enrolled on a dose level for which the safety has already&#xD;
             been determined.&#xD;
&#xD;
        Patients must be able to understand and be willing to sign a written informed consent&#xD;
        document.&#xD;
&#xD;
        INCLUSION CRITERIA:&#xD;
&#xD;
        (Expansion Phase Only)&#xD;
&#xD;
        The following inclusion criteria apply specifically to patients being considered for the&#xD;
        expansion phase of the protocol.&#xD;
&#xD;
          1. Subjects with epidermal growth factor receptor (EGFR)-mutated lung cancer may continue&#xD;
             erlotinib if they have been on the drug for greater than or equal to 3 months with&#xD;
             stable disease or a response. Erlotinib may also be continued in the case of a&#xD;
             progressing tumor after prior response (or &gt; 6 months stable disease).&#xD;
&#xD;
          2. Patients with Estrogen receptor positive (ER+) breast cancer being treated with&#xD;
             hormonal therapy (selective estrogen receptor modulator or aromatase inhibitor) who&#xD;
             have rising tumor markers as evidence of disease progression or metastatic disease on&#xD;
             scans may continue on hormonal therapy while being treated with vaccine.&#xD;
&#xD;
          3. Patients with Her2+ breast cancer receiving Her2-directed therapy (e.g. trastuzumab)&#xD;
             may continue on that therapy when enrolling into a dose level for which safety has&#xD;
             been established.&#xD;
&#xD;
          4. Subjects with metastatic colorectal cancer may continue &quot;maintenance&quot; therapy with&#xD;
             capecitabine and/or bevacizumab.&#xD;
&#xD;
        EXCLUSION CRITERIA:&#xD;
&#xD;
          1. Concurrent treatment for cancer, with specific exceptions noted in inclusion criteria.&#xD;
&#xD;
          2. Chronic hepatitis B or C infection, because potential immune impairment caused by&#xD;
             these disorders may diminish the effectiveness of this immunologic therapy.&#xD;
&#xD;
          3. Any significant disease that, in the opinion of the investigator, may impair the&#xD;
             patient's tolerance of study treatment.&#xD;
&#xD;
          4. Significant dementia, altered mental status, or any psychiatric condition that would&#xD;
             prohibit the understanding or rendering of informed consent.&#xD;
&#xD;
          5. Active autoimmune diseases requiring treatment or a history of autoimmune disease that&#xD;
             might be stimulated by vaccine treatment. This requirement is due to the potential&#xD;
             risks of exacerbating autoimmunity. However, patients with vitiligo or clinically&#xD;
             stable autoimmune endocrine disease who are on appropriate replacement therapy (if&#xD;
             such therapy is indicated) are eligible.&#xD;
&#xD;
          6. Concurrent use of systemic steroids, except for physiologic doses of systemic steroid&#xD;
             replacement or local (topical, nasal, or inhaled) steroid use. Limited pharmacologic&#xD;
             doses of systemic steroids (e.g., in patients with exacerbations of reactive airway&#xD;
             disease or to prevent intravenous (I.V.) contrast allergic reaction or anaphylaxis in&#xD;
             patients who have known contrast allergies) are allowed.&#xD;
&#xD;
          7. Patients who are receiving any other investigational agents within 28 days before&#xD;
             start of study treatment.&#xD;
&#xD;
          8. Patients with untreated central nervous system metastases or local treatment of brain&#xD;
             metastases within the last 6 months. Patients with stable brain metastasis for 6&#xD;
             months post-intervention are eligible. Subjects with chordoma will be eligible&#xD;
             regardless of site of disease if other eligibility criteria are met.&#xD;
&#xD;
          9. History of allergic reactions attributed to compounds of similar chemical or biologic&#xD;
             composition to MVA-brachyury-TRICOM or other agents used in study.&#xD;
&#xD;
         10. Serious or uncontrolled intercurrent illness including, but not limited to, ongoing or&#xD;
             active infection, symptomatic congestive heart failure, unstable angina pectoris,&#xD;
             cardiac arrhythmia, or psychiatric illness/social situations that, in the opinion of&#xD;
             the investigator, would limit compliance with study requirements.&#xD;
&#xD;
         11. Pregnant women are excluded from this study due to the unknown effects of the&#xD;
             MVAbrachyury-TRICOM vaccine on the fetus or infant. Because there is an unknown but&#xD;
             potential risk for adverse events in nursing infants secondary to treatment of the&#xD;
             mother with MVA-brachyury-TRICOM, breastfeeding should be discontinued if the mother&#xD;
             is treated with MVA-brachyury-TRICOM. These potential risks may also apply to other&#xD;
             agents used in this study.&#xD;
&#xD;
         12. Human immunodeficiency viruses (HIV)-positive patients are ineligible because of the&#xD;
             potential for decreased immune response to the vaccine.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>100 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>James L Gulley, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>National Cancer Institute (NCI)</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>National Institutes of Health Clinical Center, 9000 Rockville Pike</name>
      <address>
        <city>Bethesda</city>
        <state>Maryland</state>
        <zip>20892</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Hodge JW, Sabzevari H, Yafal AG, Gritz L, Lorenz MG, Schlom J. A triad of costimulatory molecules synergize to amplify T-cell activation. Cancer Res. 1999 Nov 15;59(22):5800-7.</citation>
    <PMID>10582702</PMID>
  </reference>
  <reference>
    <citation>Fernando RI, Litzinger M, Trono P, Hamilton DH, Schlom J, Palena C. The T-box transcription factor Brachyury promotes epithelial-mesenchymal transition in human tumor cells. J Clin Invest. 2010 Feb;120(2):533-44. doi: 10.1172/JCI38379. Epub 2010 Jan 11.</citation>
    <PMID>20071775</PMID>
  </reference>
  <reference>
    <citation>Heery CR, Palena C, McMahon S, Donahue RN, Lepone LM, Grenga I, Dirmeier U, Cordes L, Marté J, Dahut W, Singh H, Madan RA, Fernando RI, Hamilton DH, Schlom J, Gulley JL. Phase I Study of a Poxviral TRICOM-Based Vaccine Directed Against the Transcription Factor Brachyury. Clin Cancer Res. 2017 Nov 15;23(22):6833-6845. doi: 10.1158/1078-0432.CCR-17-1087. Epub 2017 Aug 30.</citation>
    <PMID>28855356</PMID>
  </reference>
  <verification_date>January 2021</verification_date>
  <study_first_submitted>June 28, 2014</study_first_submitted>
  <study_first_submitted_qc>June 28, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 2, 2014</study_first_posted>
  <results_first_submitted>December 15, 2020</results_first_submitted>
  <results_first_submitted_qc>January 11, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">January 26, 2021</results_first_posted>
  <last_update_submitted>January 11, 2021</last_update_submitted>
  <last_update_submitted_qc>January 11, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">January 26, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>National Cancer Institute (NCI)</investigator_affiliation>
    <investigator_full_name>James Gulley, M.D.</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>Immune Response</keyword>
  <keyword>Maximum Tolerated Dose</keyword>
  <keyword>Vaccine Therapy</keyword>
  <keyword>Increased Expression of Brachyury</keyword>
  <keyword>Immunotherapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaccinia</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>September 14, 2016</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/15/NCT02179515/Prot_SAP_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Informed Consent Form</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>Yes</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>September 22, 2016</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/15/NCT02179515/ICF_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Dose Level 1 - 1 Injection - Total Dose 2 x 10^8 IU</title>
          <description>Participants received Modified Vaccinia Ankara (MVA)-brachyury-modified vaccinia Ankara (MVA)-brachyury-B7-1, ICAM-1 (Intercellular Adhesion Molecule 1), and LFA-3 (lymphocyte function-associated antigen 3) TRICOM vaccine administered subcutaneously as 1 injection (I injection = 2 x 10^8 IU) of study drug at monthly (28 days +/- 4 days) intervals for 3 months. Patients with stable disease may continue to receive vaccine for up to 6 monthly doses.</description>
        </group>
        <group group_id="P2">
          <title>Dose Level 2 - 2 Injections - Total Dose 4 x 10^8 IU</title>
          <description>Participants received Modified Vaccinia Ankara (MVA)-brachyury-modified vaccinia Ankara (MVA)-brachyury-B7-1, ICAM-1 (Intercellular Adhesion Molecule 1), and LFA-3 (lymphocyte function-associated antigen 3) TRICOMvaccine administered subcutaneously as 2 injections (I injection = 2 x 10^8 IU) of study drug at monthly (28 days +/- 4 days) intervals for 3 months. Patients with stable disease may continue to receive vaccine for up to 6 monthly doses.</description>
        </group>
        <group group_id="P3">
          <title>Dose Level 3 - 4 Injections - Total Dose 8 x 10^8 IU</title>
          <description>Participants received Modified Vaccinia Ankara (MVA)-brachyury-modified vaccinia Ankara (MVA)-brachyury-B7-1, ICAM-1 (Intercellular Adhesion Molecule 1), and LFA-3 (lymphocyte function-associated antigen 3) TRICOM vaccine administered subcutaneously as 4 injections (I injection = 2 x 10^8 IU) of study drug at monthly (28 days +/- 4 days) intervals for 3 months. Patients with stable disease may continue to receive vaccine for up to 6 monthly doses.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="17"/>
                <participants group_id="P3" count="18"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="4"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="16"/>
                <participants group_id="P3" count="14"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>switched to alternative treatment</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>refused further treatment</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Disease progression on study</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="11"/>
                <participants group_id="P3" count="8"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Dose Level 1 - 1 Injection - Total Dose 2 x 10^8 IU</title>
          <description>Participants received Modified Vaccinia Ankara (MVA)-brachyury-modified vaccinia Ankara (MVA)-brachyury-B7-1, ICAM-1 (Intercellular Adhesion Molecule 1), and LFA-3 (lymphocyte function-associated antigen 3) TRICOM vaccine administered subcutaneously as 1 injection (I injection = 2 x 10^8 IU) of study drug at monthly (28 days +/- 4 days) intervals for 3 months. Patients with stable disease may continue to receive vaccine for up to 6 monthly doses.</description>
        </group>
        <group group_id="B2">
          <title>Dose Level 2 - 2 Injections - Total Dose 4 x 10^8 IU</title>
          <description>Participants received Modified Vaccinia Ankara (MVA)-brachyury-modified vaccinia Ankara (MVA)-brachyury-B7-1, ICAM-1 (Intercellular Adhesion Molecule 1), and LFA-3 (lymphocyte function-associated antigen 3) TRICOM vaccine administered subcutaneously as 2 injections (I injection = 2 x 10^8 IU) of study drug at monthly (28 days +/- 4 days) intervals for 3 months. Patients with stable disease may continue to receive vaccine for up to 6 monthly doses.</description>
        </group>
        <group group_id="B3">
          <title>Dose Level 3 - 4 Injections - Total Dose 8 x 10^8 IU</title>
          <description>Participants received Modified Vaccinia Ankara (MVA)-brachyury-modified vaccinia Ankara (MVA)-brachyury-B7-1, ICAM-1 (Intercellular Adhesion Molecule 1), and LFA-3 (lymphocyte function-associated antigen 3) TRICOM vaccine administered subcutaneously as 4 injections (I injection = 2 x 10^8 IU) of study drug at monthly (28 days +/- 4 days) intervals for 3 months. Patients with stable disease may continue to receive vaccine for up to 6 monthly doses.</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="3"/>
            <count group_id="B2" value="17"/>
            <count group_id="B3" value="18"/>
            <count group_id="B4" value="38"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="11"/>
                    <measurement group_id="B3" value="13"/>
                    <measurement group_id="B4" value="27"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="5"/>
                    <measurement group_id="B4" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="61.17" spread="3.4"/>
                    <measurement group_id="B2" value="60.92" spread="11.61"/>
                    <measurement group_id="B3" value="60.31" spread="12.38"/>
                    <measurement group_id="B4" value="60.65" spread="11.38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="8"/>
                    <measurement group_id="B4" value="18"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="10"/>
                    <measurement group_id="B4" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="17"/>
                    <measurement group_id="B3" value="18"/>
                    <measurement group_id="B4" value="38"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="4"/>
                    <measurement group_id="B4" value="6"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="14"/>
                    <measurement group_id="B3" value="14"/>
                    <measurement group_id="B4" value="31"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="17"/>
                    <measurement group_id="B3" value="18"/>
                    <measurement group_id="B4" value="38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Cancer Diagnosis</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Chordoma</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="5"/>
                    <measurement group_id="B4" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Ovarian Ca</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pancreatic Ca</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Colon Ca</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="4"/>
                    <measurement group_id="B4" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Lung Ca</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="3"/>
                    <measurement group_id="B4" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Breast Ca</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Prostate Ca</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cholangiocarcinoma</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Prior Treatments</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>1 Prior Treatment</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="3"/>
                    <measurement group_id="B4" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>2 Prior Treatments</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="7"/>
                    <measurement group_id="B4" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>3 Prior Treatments</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="4"/>
                    <measurement group_id="B4" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>4 Prior Treatments</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>5 Prior Treatments</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>No prior systemic therapy</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Serious and Non-serious Adverse Events Assessed by the Common Terminology Criteria for Adverse Events (CTCAE v4.0)</title>
        <description>Here is the count of participants with serious and non-serious adverse events assessed by the Common Terminology Criteria for Adverse Events (CTCAE v4.0). A non-serious adverse event is any untoward medical occurrence. A serious adverse event is an adverse event or suspected adverse reaction that results in death, a life-threatening adverse drug experience, hospitalization, disruption of the ability to conduct normal life functions, congenital anomaly/birth defect or important medical events that jeopardize the patient or subject and may require medical or surgical intervention to prevent one of the previous outcomes mentioned.</description>
        <time_frame>Date treatment consent signed to date off study, approximately 9 months and 6 days for DL1, 17 months and 3 days for DL2, and 23 months and 13 days for DL3.</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Dose Level 1 - 1 Injection - Total Dose 2 x 10^8 IU</title>
            <description>Participants received Modified Vaccinia Ankara (MVA)-brachyury-TRICOM vaccine administered subcutaneously as 1 injection (I injection = 2 x 10^8 IU) of study drug at monthly (28 days +/- 4 days) intervals for 3 months. Patients with stable disease may continue to receive vaccine for up to 6 monthly doses.</description>
          </group>
          <group group_id="O2">
            <title>Dose Level 2 - 2 Injections - Total Dose 4 x 10^8 IU</title>
            <description>Participants received Modified Vaccinia Ankara (MVA)-brachyury-TRICOM vaccine administered subcutaneously as 2 injections (I injection = 2 x 10^8 IU) of study drug at monthly (28 days +/- 4 days) intervals for 3 months. Patients with stable disease may continue to receive vaccine for up to 6 monthly doses.</description>
          </group>
          <group group_id="O3">
            <title>Dose Level 3 - 4 Injections - Total Dose 8 x 10^8 IU</title>
            <description>Participants received Modified Vaccinia Ankara (MVA)-brachyury-TRICOM vaccine administered subcutaneously as 4 injections (I injection = 2 x 10^8 IU) of study drug at monthly (28 days +/- 4 days) intervals for 3 months. Patients with stable disease may continue to receive vaccine for up to 6 monthly doses.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Serious and Non-serious Adverse Events Assessed by the Common Terminology Criteria for Adverse Events (CTCAE v4.0)</title>
          <description>Here is the count of participants with serious and non-serious adverse events assessed by the Common Terminology Criteria for Adverse Events (CTCAE v4.0). A non-serious adverse event is any untoward medical occurrence. A serious adverse event is an adverse event or suspected adverse reaction that results in death, a life-threatening adverse drug experience, hospitalization, disruption of the ability to conduct normal life functions, congenital anomaly/birth defect or important medical events that jeopardize the patient or subject and may require medical or surgical intervention to prevent one of the previous outcomes mentioned.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3"/>
                <count group_id="O2" value="17"/>
                <count group_id="O3" value="18"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="14"/>
                    <measurement group_id="O3" value="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Dose-Limiting Toxicities (DLT)</title>
        <description>Dose-limiting toxicity (DLT) will be defined as any one of the following: Any grade ≥ 3 hematologic toxicity or grade ≥ 3 non-hematologic toxicity that is possibly, probably, or definitely related to study drug, except transient (≤ 48 hour) grade 3 fatigue, local reactions, flu-like symptoms, fever, headache, and laboratory abnormalities that are not associated with organ pathology. Also any ≥ grade 2 allergic and ≥ grade 2 autoimmune reaction(s) (except endocrine-related immune toxicity) will be defined as a DLT. Any grade 3 autoimmune endocrine-related toxicity that has not resolved clinically within 7 days of initiating therapy will also be defined as a DLT. Generalized erythroderma or macular or papular rash lasting less than 7 days and not associated with desquamation will not be DLTs.</description>
        <time_frame>28 days following the first injection of vaccine.</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Dose Level 1 - 1 Injection - Total Dose 2 x 10^8 IU</title>
            <description>Participants received Modified Vaccinia Ankara (MVA)-brachyury-TRICOM vaccine administered subcutaneously as 1 injection (I injection = 2 x 10^8 IU) of study drug at monthly (28 days +/- 4 days) intervals for 3 months. Patients with stable disease may continue to receive vaccine for up to 6 monthly doses.</description>
          </group>
          <group group_id="O2">
            <title>Dose Level 2 - 2 Injections - Total Dose 4 x 10^8 IU</title>
            <description>Participants received Modified Vaccinia Ankara (MVA)-brachyury-TRICOM vaccine administered subcutaneously as 2 injections (I injection = 2 x 10^8 IU) of study drug at monthly (28 days +/- 4 days) intervals for 3 months. Patients with stable disease may continue to receive vaccine for up to 6 monthly doses.</description>
          </group>
          <group group_id="O3">
            <title>Dose Level 3 - 4 Injections - Total Dose 8 x 10^8 IU</title>
            <description>Participants received Modified Vaccinia Ankara (MVA)-brachyury-TRICOM vaccine administered subcutaneously as 4 injections (I injection = 2 x 10^8 IU) of study drug at monthly (28 days +/- 4 days) intervals for 3 months. Patients with stable disease may continue to receive vaccine for up to 6 monthly doses.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Dose-Limiting Toxicities (DLT)</title>
          <description>Dose-limiting toxicity (DLT) will be defined as any one of the following: Any grade ≥ 3 hematologic toxicity or grade ≥ 3 non-hematologic toxicity that is possibly, probably, or definitely related to study drug, except transient (≤ 48 hour) grade 3 fatigue, local reactions, flu-like symptoms, fever, headache, and laboratory abnormalities that are not associated with organ pathology. Also any ≥ grade 2 allergic and ≥ grade 2 autoimmune reaction(s) (except endocrine-related immune toxicity) will be defined as a DLT. Any grade 3 autoimmune endocrine-related toxicity that has not resolved clinically within 7 days of initiating therapy will also be defined as a DLT. Generalized erythroderma or macular or papular rash lasting less than 7 days and not associated with desquamation will not be DLTs.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3"/>
                <count group_id="O2" value="17"/>
                <count group_id="O3" value="18"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Maximum Tolerated Dose (MTD)</title>
        <description>The MTD will be the dose level at which no greater than 1/6 patients have a dose-limiting toxicity (DLT), and the next higher dose level has at least 2 patients with a DLT.</description>
        <time_frame>First 28 days of treatment.</time_frame>
        <group_list>
          <group group_id="O1">
            <title>All Participants</title>
            <description>All participants in Dose Level 1 - 1 injection - Total Dose 2 x 10^8 IU, Dose Level 2 - 2 injections - Total Dose 4 x 10^8 IU, and Dose Level 3 - 4 injections - Total Dose 8 x 10^8 IU.</description>
          </group>
        </group_list>
        <measure>
          <title>Maximum Tolerated Dose (MTD)</title>
          <description>The MTD will be the dose level at which no greater than 1/6 patients have a dose-limiting toxicity (DLT), and the next higher dose level has at least 2 patients with a DLT.</description>
          <units>10^8 IU</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="38"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">The MTD was not reached.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Grade 3 or Greater Adverse Events Possibly Related to Vaccine</title>
        <description>Number of participants with Grade 3 or greater adverse events possibly related to vaccine assessed by the Common Terminology Criteria for Adverse Events (CTCAE v4.0). Grade 3 is severe or medically significant but not immediately life-threatening. Grade 4 is life threatening consequences, and Grade 5 is death related to adverse event.</description>
        <time_frame>Date treatment consent signed to date off study, approximately 9 months and 6 days for DL1, 17 months and 3 days for DL2, and 23 months and 13 days for DL3.</time_frame>
        <population>Only one Grade 3 adverse event (diarrhea) possibly related to vaccine occurred on this trial; and no Grade 4 and 5 adverse events possibly related to vaccine.</population>
        <group_list>
          <group group_id="O1">
            <title>Dose Level 1 - 1 Injection - Total Dose 2 x 10^8 IU</title>
            <description>Participants received Modified Vaccinia Ankara (MVA)-brachyury-TRICOM vaccine administered subcutaneously as 1 injection (I injection = 2 x 10^8 IU) of study drug at monthly (28 days +/- 4 days) intervals for 3 months. Patients with stable disease may continue to receive vaccine for up to 6 monthly doses.</description>
          </group>
          <group group_id="O2">
            <title>Dose Level 2 - 2 Injections - Total Dose 4 x 10^8 IU</title>
            <description>Participants received Modified Vaccinia Ankara (MVA)-brachyury-TRICOM vaccine administered subcutaneously as 2 injections (I injection = 2 x 10^8 IU) of study drug at monthly (28 days +/- 4 days) intervals for 3 months. Patients with stable disease may continue to receive vaccine for up to 6 monthly doses.</description>
          </group>
          <group group_id="O3">
            <title>Dose Level 3 - 4 Injections - Total Dose 8 x 10^8 IU</title>
            <description>Participants received Modified Vaccinia Ankara (MVA)-brachyury-TRICOM vaccine administered subcutaneously as 4 injections (I injection = 2 x 10^8 IU) of study drug at monthly (28 days +/- 4 days) intervals for 3 months. Patients with stable disease may continue to receive vaccine for up to 6 monthly doses.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Grade 3 or Greater Adverse Events Possibly Related to Vaccine</title>
          <description>Number of participants with Grade 3 or greater adverse events possibly related to vaccine assessed by the Common Terminology Criteria for Adverse Events (CTCAE v4.0). Grade 3 is severe or medically significant but not immediately life-threatening. Grade 4 is life threatening consequences, and Grade 5 is death related to adverse event.</description>
          <population>Only one Grade 3 adverse event (diarrhea) possibly related to vaccine occurred on this trial; and no Grade 4 and 5 adverse events possibly related to vaccine.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3"/>
                <count group_id="O2" value="17"/>
                <count group_id="O3" value="18"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Brachyury-Specific T-cell Responses Developed After 1, 2, and 3 Vaccinations</title>
        <description>A fluorescence activated cell sorting (FACS)-based assay for cluster of differentiation 4 (CD4) or cluster of differentiation 8 (CD8) T-cells expressing the cytokines interferon (IFN) gamma, interleukin 2 (IL2), and tumor necrosis factor (TNF) alpha, and/or cluster of differentiation 107a (CD107a) (a marker for lytic potential) was used to determine the numbers of participants showing development or enhancement of the level of brachyury-specific T-cells after vaccination.</description>
        <time_frame>Baseline (pre-vaccination), approximately day 29 (after 1 vaccination), approximately day 57 (after 2 vaccinations), and approximately day 85 (after 3 vaccinations)</time_frame>
        <population>Sufficient peripheral blood mononuclear cells (PBMCs) were available before and after vaccination from 34 of 38 patients to analyze brachyury-specific CD4 and CD8 T-cell responses.</population>
        <group_list>
          <group group_id="O1">
            <title>Dose Level 1 - 1 Injection - Total Dose 2 x 10^8 IU</title>
            <description>Participants received Modified Vaccinia Ankara (MVA)-brachyury-TRICOM vaccine administered subcutaneously as 1 injection (I injection = 2 x 10^8 IU) of study drug at monthly (28 days +/- 4 days) intervals for 3 months. Patients with stable disease may continue to receive vaccine for up to 6 monthly doses.</description>
          </group>
          <group group_id="O2">
            <title>Dose Level 2 - 2 Injections - Total Dose 4 x 10^8 IU</title>
            <description>Participants received Modified Vaccinia Ankara (MVA)-brachyury-TRICOM vaccine administered subcutaneously as 2 injections (I injection = 2 x 10^8 IU) of study drug at monthly (28 days +/- 4 days) intervals for 3 months. Patients with stable disease may continue to receive vaccine for up to 6 monthly doses.</description>
          </group>
          <group group_id="O3">
            <title>Dose Level 3 - 4 Injections - Total Dose 8 x 10^8 IU</title>
            <description>Participants received Modified Vaccinia Ankara (MVA)-brachyury-TRICOM vaccine administered subcutaneously as 4 injections (I injection = 2 x 10^8 IU) of study drug at monthly (28 days +/- 4 days) intervals for 3 months. Patients with stable disease may continue to receive vaccine for up to 6 monthly doses.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Brachyury-Specific T-cell Responses Developed After 1, 2, and 3 Vaccinations</title>
          <description>A fluorescence activated cell sorting (FACS)-based assay for cluster of differentiation 4 (CD4) or cluster of differentiation 8 (CD8) T-cells expressing the cytokines interferon (IFN) gamma, interleukin 2 (IL2), and tumor necrosis factor (TNF) alpha, and/or cluster of differentiation 107a (CD107a) (a marker for lytic potential) was used to determine the numbers of participants showing development or enhancement of the level of brachyury-specific T-cells after vaccination.</description>
          <population>Sufficient peripheral blood mononuclear cells (PBMCs) were available before and after vaccination from 34 of 38 patients to analyze brachyury-specific CD4 and CD8 T-cell responses.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3"/>
                <count group_id="O2" value="15"/>
                <count group_id="O3" value="16"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>CD107a + CD4 T-cell response (d29 vs pre)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="3"/>
                    <count group_id="O2" value="15"/>
                    <count group_id="O3" value="16"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="4"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>IFN gamma + CD4 T-cell response (d29 vs pre)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="3"/>
                    <count group_id="O2" value="15"/>
                    <count group_id="O3" value="16"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>IL2 + CD4 T-cell response (d29 vs pre)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="3"/>
                    <count group_id="O2" value="15"/>
                    <count group_id="O3" value="16"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>TNF alpha + CD4 T-cell response (d29 vs pre)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="3"/>
                    <count group_id="O2" value="15"/>
                    <count group_id="O3" value="16"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="4"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD107a + CD8 T-cell response (d29 vs pre)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="3"/>
                    <count group_id="O2" value="15"/>
                    <count group_id="O3" value="16"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>IFN gamma + CD8 T-cell response (d29 vs pre)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="3"/>
                    <count group_id="O2" value="15"/>
                    <count group_id="O3" value="16"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="6"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>IL2 + CD8 T-cell response (d29 vs pre)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="3"/>
                    <count group_id="O2" value="15"/>
                    <count group_id="O3" value="16"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>TNF alpha + CD8 T-cell response (d29 vs pre)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="3"/>
                    <count group_id="O2" value="15"/>
                    <count group_id="O3" value="16"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="4"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any T-cell response (d29 vs pre)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="3"/>
                    <count group_id="O2" value="15"/>
                    <count group_id="O3" value="16"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="9"/>
                    <measurement group_id="O3" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD107a + CD4 T-cell response (d57 vs pre)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="3"/>
                    <count group_id="O2" value="15"/>
                    <count group_id="O3" value="16"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>IFN gamma + CD4 T-cell response (d57 vs pre)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="3"/>
                    <count group_id="O2" value="15"/>
                    <count group_id="O3" value="16"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>IL2 + CD4 T-cell response (d57 vs pre)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="3"/>
                    <count group_id="O2" value="15"/>
                    <count group_id="O3" value="16"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>TNF alpha + CD4 T-cell response (d57 vs pre)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="3"/>
                    <count group_id="O2" value="15"/>
                    <count group_id="O3" value="16"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD107a + CD8 T-cell response (d57 vs pre)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="3"/>
                    <count group_id="O2" value="15"/>
                    <count group_id="O3" value="16"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>IFN gamma + CD8 T-cell response (d57 vs pre)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="3"/>
                    <count group_id="O2" value="15"/>
                    <count group_id="O3" value="16"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>IL2 + CD8 T-cell response (d57 vs pre)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="3"/>
                    <count group_id="O2" value="15"/>
                    <count group_id="O3" value="16"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>TNF alpha + CD8 T-cell response (d57 vs pre)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="3"/>
                    <count group_id="O2" value="15"/>
                    <count group_id="O3" value="16"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="5"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any T-cell response (d57 vs pre)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="3"/>
                    <count group_id="O2" value="15"/>
                    <count group_id="O3" value="16"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="6"/>
                    <measurement group_id="O3" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD107a + CD4 T-cell response (d85 vs pre)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="3"/>
                    <count group_id="O2" value="14"/>
                    <count group_id="O3" value="15"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>IFN gamma + CD4 T-cell response (d85 vs pre)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="3"/>
                    <count group_id="O2" value="14"/>
                    <count group_id="O3" value="15"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>IL2 + CD4 T-cell response (d85 vs pre)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="3"/>
                    <count group_id="O2" value="14"/>
                    <count group_id="O3" value="15"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>TNF alpha + CD4 T-cell response (d85 vs pre)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="3"/>
                    <count group_id="O2" value="14"/>
                    <count group_id="O3" value="15"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD107a + CD8 T-cell response (d85 vs pre)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="3"/>
                    <count group_id="O2" value="14"/>
                    <count group_id="O3" value="15"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>IFN gamma + CD8 T-cell response (d85 vs pre)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="3"/>
                    <count group_id="O2" value="14"/>
                    <count group_id="O3" value="15"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>IL2 + CD8 T-cell response (d85 vs pre)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="3"/>
                    <count group_id="O2" value="14"/>
                    <count group_id="O3" value="15"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>TNF alpha + CD8 T-cell response (d85 vs pre)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="3"/>
                    <count group_id="O2" value="14"/>
                    <count group_id="O3" value="15"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any T-cell response (d85 vs pre)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="3"/>
                    <count group_id="O2" value="14"/>
                    <count group_id="O3" value="15"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="5"/>
                    <measurement group_id="O3" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Total Peripheral Blood Mononuclear Cells (PBMCs) in Peripheral Blood Before Vaccination, and After 1 and 3 Vaccinations</title>
        <description>Blood samples collected were analyzed by multicolor flow cytometry in PBMCs for cluster of differentiation 4 (CD4), cluster of differentiation 8 (CD8), Natural Killer (NK), Natural Killer T (NKT), conventional dendritic cell (cDC), plasmacytoid dendritic cell (pDC), myeloid-derived suppressor cell (MDSC) and Tregs. Changes in levels PBMC subsets was a descriptive result with median and interquartile range reported. No formal statistical analysis by dose level was performed given the small sample size.</description>
        <time_frame>Pre (Baseline), and approximately D29 (Post 1 vaccination) and D85 (post 3 vaccinations)</time_frame>
        <population>Sufficient peripheral blood mononuclear cells (PBMCs) were available before and after vaccination from 36 of 38 patients to analyze peripheral immune cell subsets.</population>
        <group_list>
          <group group_id="O1">
            <title>Dose Level 1 - 1 Injection - Total Dose 2 x 10^8 IU</title>
            <description>Participants received Modified Vaccinia Ankara (MVA)-brachyury-TRICOM vaccine administered subcutaneously as 1 injection (I injection = 2 x 10^8 IU) of study drug at monthly (28 days +/- 4 days) intervals for 3 months. Patients with stable disease may continue to receive vaccine for up to 6 monthly doses.</description>
          </group>
          <group group_id="O2">
            <title>Dose Level 2 - 2 Injections - Total Dose 4 x 10^8 IU</title>
            <description>Participants received Modified Vaccinia Ankara (MVA)-brachyury-TRICOM vaccine administered subcutaneously as 2 injections (I injection = 2 x 10^8 IU) of study drug at monthly (28 days +/- 4 days) intervals for 3 months. Patients with stable disease may continue to receive vaccine for up to 6 monthly doses.</description>
          </group>
          <group group_id="O3">
            <title>Dose Level 3 - 4 Injections - Total Dose 8 x 10^8 IU</title>
            <description>Participants received Modified Vaccinia Ankara (MVA)-brachyury-TRICOM vaccine administered subcutaneously as 4 injections (I injection = 2 x 10^8 IU) of study drug at monthly (28 days +/- 4 days) intervals for 3 months. Patients with stable disease may continue to receive vaccine for up to 6 monthly doses.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Total Peripheral Blood Mononuclear Cells (PBMCs) in Peripheral Blood Before Vaccination, and After 1 and 3 Vaccinations</title>
          <description>Blood samples collected were analyzed by multicolor flow cytometry in PBMCs for cluster of differentiation 4 (CD4), cluster of differentiation 8 (CD8), Natural Killer (NK), Natural Killer T (NKT), conventional dendritic cell (cDC), plasmacytoid dendritic cell (pDC), myeloid-derived suppressor cell (MDSC) and Tregs. Changes in levels PBMC subsets was a descriptive result with median and interquartile range reported. No formal statistical analysis by dose level was performed given the small sample size.</description>
          <population>Sufficient peripheral blood mononuclear cells (PBMCs) were available before and after vaccination from 36 of 38 patients to analyze peripheral immune cell subsets.</population>
          <units>Percentage of Total PBMC's</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3"/>
                <count group_id="O2" value="16"/>
                <count group_id="O3" value="17"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>CD4 Pre</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="3"/>
                    <count group_id="O2" value="16"/>
                    <count group_id="O3" value="17"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="24.31" lower_limit="14.78" upper_limit="38.24"/>
                    <measurement group_id="O2" value="32.64" lower_limit="27.63" upper_limit="40.74"/>
                    <measurement group_id="O3" value="32.89" lower_limit="22.61" upper_limit="37.37"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD4 D29</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="3"/>
                    <count group_id="O2" value="16"/>
                    <count group_id="O3" value="17"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23.68" lower_limit="13.15" upper_limit="36.09"/>
                    <measurement group_id="O2" value="34.99" lower_limit="23.61" upper_limit="39.35"/>
                    <measurement group_id="O3" value="29.86" lower_limit="20.99" upper_limit="36.08"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD4 D85</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="3"/>
                    <count group_id="O2" value="14"/>
                    <count group_id="O3" value="15"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="27.70" lower_limit="13.09" upper_limit="39.84"/>
                    <measurement group_id="O2" value="30.35" lower_limit="25.55" upper_limit="36.67"/>
                    <measurement group_id="O3" value="29.87" lower_limit="25.77" upper_limit="36.65"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD8 Pre</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="3"/>
                    <count group_id="O2" value="16"/>
                    <count group_id="O3" value="17"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.51" lower_limit="4.90" upper_limit="14.31"/>
                    <measurement group_id="O2" value="16.85" lower_limit="10.20" upper_limit="23.58"/>
                    <measurement group_id="O3" value="12.27" lower_limit="9.28" upper_limit="16.34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD8 D29</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="3"/>
                    <count group_id="O2" value="16"/>
                    <count group_id="O3" value="17"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.83" lower_limit="3.73" upper_limit="13.43"/>
                    <measurement group_id="O2" value="16.28" lower_limit="9.55" upper_limit="24.45"/>
                    <measurement group_id="O3" value="10.96" lower_limit="9.18" upper_limit="17.43"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD8 D85</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="3"/>
                    <count group_id="O2" value="14"/>
                    <count group_id="O3" value="15"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.92" lower_limit="5.71" upper_limit="13.99"/>
                    <measurement group_id="O2" value="17.17" lower_limit="12.29" upper_limit="26.14"/>
                    <measurement group_id="O3" value="13.99" lower_limit="11.78" upper_limit="20.43"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Treg Pre</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="3"/>
                    <count group_id="O2" value="16"/>
                    <count group_id="O3" value="17"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.19" lower_limit="1.00" upper_limit="2.41"/>
                    <measurement group_id="O2" value="1.50" lower_limit="1.21" upper_limit="1.93"/>
                    <measurement group_id="O3" value="1.07" lower_limit="0.77" upper_limit="1.53"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Treg D29</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="3"/>
                    <count group_id="O2" value="16"/>
                    <count group_id="O3" value="17"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.71" lower_limit="1.23" upper_limit="1.98"/>
                    <measurement group_id="O2" value="1.40" lower_limit="1.20" upper_limit="1.78"/>
                    <measurement group_id="O3" value="1.34" lower_limit="0.88" upper_limit="1.65"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Treg D85</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="3"/>
                    <count group_id="O2" value="14"/>
                    <count group_id="O3" value="15"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.09" lower_limit="1.19" upper_limit="2.30"/>
                    <measurement group_id="O2" value="1.26" lower_limit="0.80" upper_limit="1.65"/>
                    <measurement group_id="O3" value="1.22" lower_limit="0.74" upper_limit="1.63"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>B cells Pre</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="3"/>
                    <count group_id="O2" value="16"/>
                    <count group_id="O3" value="17"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15.89" lower_limit="10.45" upper_limit="21.33"/>
                    <measurement group_id="O2" value="7.76" lower_limit="5.32" upper_limit="15.31"/>
                    <measurement group_id="O3" value="10.41" lower_limit="6.20" upper_limit="12.44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>B cells D29</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="3"/>
                    <count group_id="O2" value="16"/>
                    <count group_id="O3" value="17"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15.46" lower_limit="10.50" upper_limit="20.42"/>
                    <measurement group_id="O2" value="7.52" lower_limit="5.54" upper_limit="15.24"/>
                    <measurement group_id="O3" value="8.56" lower_limit="6.55" upper_limit="11.97"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>B cells D85</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="3"/>
                    <count group_id="O2" value="14"/>
                    <count group_id="O3" value="15"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14.54" lower_limit="12.17" upper_limit="16.91"/>
                    <measurement group_id="O2" value="6.49" lower_limit="5.32" upper_limit="11.82"/>
                    <measurement group_id="O3" value="10.26" lower_limit="6.30" upper_limit="14.01"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>NK cells Pre</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="3"/>
                    <count group_id="O2" value="16"/>
                    <count group_id="O3" value="17"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.47" lower_limit="5.35" upper_limit="8.33"/>
                    <measurement group_id="O2" value="6.07" lower_limit="4.23" upper_limit="9.07"/>
                    <measurement group_id="O3" value="8.93" lower_limit="4.74" upper_limit="13.82"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>NK cells D29</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="3"/>
                    <count group_id="O2" value="16"/>
                    <count group_id="O3" value="17"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.51" lower_limit="5.40" upper_limit="8.28"/>
                    <measurement group_id="O2" value="7.32" lower_limit="5.82" upper_limit="11.97"/>
                    <measurement group_id="O3" value="12.34" lower_limit="6.90" upper_limit="18.94"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>NK cells D85</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="3"/>
                    <count group_id="O2" value="14"/>
                    <count group_id="O3" value="15"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.30" lower_limit="6.98" upper_limit="18.52"/>
                    <measurement group_id="O2" value="7.83" lower_limit="6.50" upper_limit="9.57"/>
                    <measurement group_id="O3" value="12.29" lower_limit="7.55" upper_limit="14.45"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>NK-T cells Pre</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="3"/>
                    <count group_id="O2" value="16"/>
                    <count group_id="O3" value="17"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.29" lower_limit="0.24" upper_limit="0.52"/>
                    <measurement group_id="O2" value="1.69" lower_limit="1.20" upper_limit="5.93"/>
                    <measurement group_id="O3" value="1.90" lower_limit="1.00" upper_limit="2.78"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>NK-T cells D29</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="3"/>
                    <count group_id="O2" value="16"/>
                    <count group_id="O3" value="17"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.35" lower_limit="0.31" upper_limit="0.55"/>
                    <measurement group_id="O2" value="2.06" lower_limit="0.95" upper_limit="6.09"/>
                    <measurement group_id="O3" value="2.23" lower_limit="0.85" upper_limit="2.75"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>NK-T cells D85</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="3"/>
                    <count group_id="O2" value="14"/>
                    <count group_id="O3" value="15"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.42" lower_limit="0.25" upper_limit="0.43"/>
                    <measurement group_id="O2" value="2.14" lower_limit="0.94" upper_limit="6.48"/>
                    <measurement group_id="O3" value="2.03" lower_limit="0.74" upper_limit="2.91"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>cDC Pre</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="3"/>
                    <count group_id="O2" value="16"/>
                    <count group_id="O3" value="17"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.24" lower_limit="0.22" upper_limit="0.58"/>
                    <measurement group_id="O2" value="0.23" lower_limit="0.13" upper_limit="0.31"/>
                    <measurement group_id="O3" value="0.27" lower_limit="0.20" upper_limit="0.40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>cDC D29</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="3"/>
                    <count group_id="O2" value="16"/>
                    <count group_id="O3" value="17"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.46" lower_limit="0.27" upper_limit="0.54"/>
                    <measurement group_id="O2" value="0.18" lower_limit="0.12" upper_limit="0.27"/>
                    <measurement group_id="O3" value="0.22" lower_limit="0.17" upper_limit="0.35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>cDC D85</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="3"/>
                    <count group_id="O2" value="14"/>
                    <count group_id="O3" value="15"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.28" lower_limit="0.14" upper_limit="0.52"/>
                    <measurement group_id="O2" value="0.18" lower_limit="0.15" upper_limit="0.24"/>
                    <measurement group_id="O3" value="0.22" lower_limit="0.16" upper_limit="0.32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>pDC Pre</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="3"/>
                    <count group_id="O2" value="16"/>
                    <count group_id="O3" value="17"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.13" lower_limit="0.12" upper_limit="0.25"/>
                    <measurement group_id="O2" value="0.15" lower_limit="0.10" upper_limit="0.22"/>
                    <measurement group_id="O3" value="0.17" lower_limit="0.10" upper_limit="0.36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>pDC D29</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="3"/>
                    <count group_id="O2" value="16"/>
                    <count group_id="O3" value="17"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.16" lower_limit="0.15" upper_limit="0.24"/>
                    <measurement group_id="O2" value="0.17" lower_limit="0.11" upper_limit="0.21"/>
                    <measurement group_id="O3" value="0.22" lower_limit="0.12" upper_limit="0.36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>pDC D85</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="3"/>
                    <count group_id="O2" value="14"/>
                    <count group_id="O3" value="15"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.07" lower_limit="0.07" upper_limit="0.39"/>
                    <measurement group_id="O2" value="0.15" lower_limit="0.12" upper_limit="0.21"/>
                    <measurement group_id="O3" value="0.23" lower_limit="0.14" upper_limit="0.30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>MDSC Pre</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="3"/>
                    <count group_id="O2" value="16"/>
                    <count group_id="O3" value="17"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13.17" lower_limit="6.84" upper_limit="19.50"/>
                    <measurement group_id="O2" value="7.11" lower_limit="4.86" upper_limit="10.69"/>
                    <measurement group_id="O3" value="7.04" lower_limit="4.92" upper_limit="10.18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>MDSC D29</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="3"/>
                    <count group_id="O2" value="16"/>
                    <count group_id="O3" value="17"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.53" lower_limit="6.42" upper_limit="10.63"/>
                    <measurement group_id="O2" value="6.69" lower_limit="4.27" upper_limit="11.29"/>
                    <measurement group_id="O3" value="7.66" lower_limit="4.91" upper_limit="10.54"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>MDSC D85</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="3"/>
                    <count group_id="O2" value="14"/>
                    <count group_id="O3" value="15"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.34" lower_limit="6.52" upper_limit="10.16"/>
                    <measurement group_id="O2" value="9.15" lower_limit="5.11" upper_limit="11.94"/>
                    <measurement group_id="O3" value="8.83" lower_limit="4.58" upper_limit="11.42"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Positive Anti-Brachyury Antibodies</title>
        <description>A positive brachyury antibody titer consisted of an absorbance to brachyury protein that was twice that obtained with the negative control protein Bovine serum albumin (BSA). A positive titer after vaccination may be indicative of an immune response to the vaccine.</description>
        <time_frame>Pre (Baseline), and approximately D29 (Post 1 vaccination), D57 (post 2 vaccinations) and D85 (post 3 vaccinations)</time_frame>
        <population>Sufficient serum was available before and after vaccination from 34 of 38 patients to analyze anti-brachyury antibodies.</population>
        <group_list>
          <group group_id="O1">
            <title>Dose Level 1 - 1 Injection - Total Dose 2 x 10^8 IU</title>
            <description>Participants received Modified Vaccinia Ankara (MVA)-brachyury-TRICOM vaccine administered subcutaneously as 1 injection (I injection = 2 x 10^8 IU) of study drug at monthly (28 days +/- 4 days) intervals for 3 months. Patients with stable disease may continue to receive vaccine for up to 6 monthly doses.</description>
          </group>
          <group group_id="O2">
            <title>Dose Level 2 - 2 Injections - Total Dose 4 x 10^8 IU</title>
            <description>Participants received Modified Vaccinia Ankara (MVA)-brachyury-TRICOM vaccine administered subcutaneously as 2 injections (I injection = 2 x 10^8 IU) of study drug at monthly (28 days +/- 4 days) intervals for 3 months. Patients with stable disease may continue to receive vaccine for up to 6 monthly doses.</description>
          </group>
          <group group_id="O3">
            <title>Dose Level 3 - 4 Injections - Total Dose 8 x 10^8 IU</title>
            <description>Participants received Modified Vaccinia Ankara (MVA)-brachyury-TRICOM vaccine administered subcutaneously as 4 injections (I injection = 2 x 10^8 IU) of study drug at monthly (28 days +/- 4 days) intervals for 3 months. Patients with stable disease may continue to receive vaccine for up to 6 monthly doses.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Positive Anti-Brachyury Antibodies</title>
          <description>A positive brachyury antibody titer consisted of an absorbance to brachyury protein that was twice that obtained with the negative control protein Bovine serum albumin (BSA). A positive titer after vaccination may be indicative of an immune response to the vaccine.</description>
          <population>Sufficient serum was available before and after vaccination from 34 of 38 patients to analyze anti-brachyury antibodies.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3"/>
                <count group_id="O2" value="15"/>
                <count group_id="O3" value="16"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Anti-Brachyury Antibodies Pre</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="3"/>
                    <count group_id="O2" value="15"/>
                    <count group_id="O3" value="16"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-Brachyury Antibodies D29</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="3"/>
                    <count group_id="O2" value="15"/>
                    <count group_id="O3" value="16"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-Brachyury Antibodies D57</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="3"/>
                    <count group_id="O2" value="14"/>
                    <count group_id="O3" value="16"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-Brachyury Antibodies D85</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="3"/>
                    <count group_id="O2" value="14"/>
                    <count group_id="O3" value="15"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Changes in Serum Cytokines Soluble CD27 (sCD27) and Soluble Factors</title>
        <description>Serum levels of Soluble CD27 (sCD27) were determined by enzyme-linked immunosorbent assay (ELISA) pre and post vaccination. Changes in levels of serum cytokines and soluble factors was a descriptive result with median and interquartile range reported. No formal statistical analysis by dose level was performed given the small sample size.</description>
        <time_frame>Pre (Baseline), and approximately D29 (Post 1 vaccination), and D85 (post 3 vaccinations)</time_frame>
        <population>Sufficient serum was available before and after vaccination from 36 of 38 patients to analyze serum cytokines and soluble factors.</population>
        <group_list>
          <group group_id="O1">
            <title>Dose Level 1 - 1 Injection - Total Dose 2 x 10^8 IU</title>
            <description>Participants received Modified Vaccinia Ankara (MVA)-brachyury-TRICOM vaccine administered subcutaneously as 1 injection (I injection = 2 x 10^8 IU) of study drug at monthly (28 days +/- 4 days) intervals for 3 months. Patients with stable disease may continue to receive vaccine for up to 6 monthly doses.</description>
          </group>
          <group group_id="O2">
            <title>Dose Level 2 - 2 Injections - Total Dose 4 x 10^8 IU</title>
            <description>Participants received Modified Vaccinia Ankara (MVA)-brachyury-TRICOM vaccine administered subcutaneously as 2 injections (I injection = 2 x 10^8 IU) of study drug at monthly (28 days +/- 4 days) intervals for 3 months. Patients with stable disease may continue to receive vaccine for up to 6 monthly doses.</description>
          </group>
          <group group_id="O3">
            <title>Dose Level 3 - 4 Injections - Total Dose 8 x 10^8 IU</title>
            <description>Participants received Modified Vaccinia Ankara (MVA)-brachyury-TRICOM vaccine administered subcutaneously as 4 injections (I injection = 2 x 10^8 IU) of study drug at monthly (28 days +/- 4 days) intervals for 3 months. Patients with stable disease may continue to receive vaccine for up to 6 monthly doses.</description>
          </group>
        </group_list>
        <measure>
          <title>Changes in Serum Cytokines Soluble CD27 (sCD27) and Soluble Factors</title>
          <description>Serum levels of Soluble CD27 (sCD27) were determined by enzyme-linked immunosorbent assay (ELISA) pre and post vaccination. Changes in levels of serum cytokines and soluble factors was a descriptive result with median and interquartile range reported. No formal statistical analysis by dose level was performed given the small sample size.</description>
          <population>Sufficient serum was available before and after vaccination from 36 of 38 patients to analyze serum cytokines and soluble factors.</population>
          <units>U/mL</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3"/>
                <count group_id="O2" value="16"/>
                <count group_id="O3" value="17"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>sCD27 Pre</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="3"/>
                    <count group_id="O2" value="16"/>
                    <count group_id="O3" value="17"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20.53" lower_limit="1.20" upper_limit="51.33"/>
                    <measurement group_id="O2" value="19.34" lower_limit="11.24" upper_limit="23.57"/>
                    <measurement group_id="O3" value="12.10" lower_limit="7.42" upper_limit="18.88"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>sCD27 D29</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="3"/>
                    <count group_id="O2" value="16"/>
                    <count group_id="O3" value="17"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25.65" lower_limit="16.30" upper_limit="47.38"/>
                    <measurement group_id="O2" value="18.40" lower_limit="8.02" upper_limit="27.10"/>
                    <measurement group_id="O3" value="15.12" lower_limit="11.95" upper_limit="25.82"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>sCD27 D85</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="3"/>
                    <count group_id="O2" value="14"/>
                    <count group_id="O3" value="15"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22.35" lower_limit="19.03" upper_limit="24.15"/>
                    <measurement group_id="O2" value="14.50" lower_limit="9.06" upper_limit="25.38"/>
                    <measurement group_id="O3" value="16.33" lower_limit="12.10" upper_limit="25.99"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Changes in Serum Cytokines Soluble CD40 Ligand (sCD40L) and Soluble Factors</title>
        <description>Serum levels of sCD40L, were determined by enzyme-linked immunosorbent assay (ELISA) pre and post vaccination. Changes in levels of serum cytokines and soluble factors was a descriptive result with median and interquartile range reported. No formal statistical analysis by dose level was performed given the small sample size.</description>
        <time_frame>Pre (Baseline), and approximately D29 (Post 1 vaccination), and D85 (post 3 vaccinations)</time_frame>
        <population>Sufficient serum was available before and after vaccination from 36 of 38 patients to analyze serum cytokines and soluble factors.</population>
        <group_list>
          <group group_id="O1">
            <title>Dose Level 1 - 1 Injection - Total Dose 2 x 10^8 IU</title>
            <description>Participants received Modified Vaccinia Ankara (MVA)-brachyury-modified vaccinia Ankara (MVA)-brachyury-B7-1, ICAM-1 (Intercellular Adhesion Molecule 1), and LFA-3 (lymphocyte function-associated antigen 3) TRICOM vaccine administered subcutaneously as 1 injection (I injection = 2 x 10^8 IU) of study drug at monthly (28 days +/- 4 days) intervals for 3 months. Patients with stable disease may continue to receive vaccine for up to 6 monthly doses.</description>
          </group>
          <group group_id="O2">
            <title>Dose Level 2 - 2 Injections - Total Dose 4 x 10^8 IU</title>
            <description>Participants received Modified Vaccinia Ankara (MVA)-brachyury-modified vaccinia Ankara (MVA)-brachyury-B7-1, ICAM-1 (Intercellular Adhesion Molecule 1), and LFA-3 (lymphocyte function-associated antigen 3) TRICOM vaccine administered subcutaneously as 2 injections (I injection = 2 x 10^8 IU) of study drug at monthly (28 days +/- 4 days) intervals for 3 months. Patients with stable disease may continue to receive vaccine for up to 6 monthly doses.</description>
          </group>
          <group group_id="O3">
            <title>Dose Level 3 - 4 Injections - Total Dose 8 x 10^8 IU</title>
            <description>Participants received Modified Vaccinia Ankara (MVA)-brachyury-modified vaccinia Ankara (MVA)-brachyury-B7-1, ICAM-1 (Intercellular Adhesion Molecule 1), and LFA-3 (lymphocyte function-associated antigen 3) TRICOM vaccine administered subcutaneously as 4 injections (I injection = 2 x 10^8 IU) of study drug at monthly (28 days +/- 4 days) intervals for 3 months. Patients with stable disease may continue to receive vaccine for up to 6 monthly doses.</description>
          </group>
        </group_list>
        <measure>
          <title>Changes in Serum Cytokines Soluble CD40 Ligand (sCD40L) and Soluble Factors</title>
          <description>Serum levels of sCD40L, were determined by enzyme-linked immunosorbent assay (ELISA) pre and post vaccination. Changes in levels of serum cytokines and soluble factors was a descriptive result with median and interquartile range reported. No formal statistical analysis by dose level was performed given the small sample size.</description>
          <population>Sufficient serum was available before and after vaccination from 36 of 38 patients to analyze serum cytokines and soluble factors.</population>
          <units>ng/mL</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3"/>
                <count group_id="O2" value="16"/>
                <count group_id="O3" value="17"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>sCD40L Pre</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="3"/>
                    <count group_id="O2" value="16"/>
                    <count group_id="O3" value="17"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.76" lower_limit="1.55" upper_limit="20.34"/>
                    <measurement group_id="O2" value="17.52" lower_limit="11.98" upper_limit="22.03"/>
                    <measurement group_id="O3" value="18.94" lower_limit="14.63" upper_limit="26.29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>sCD40L D29</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="3"/>
                    <count group_id="O2" value="16"/>
                    <count group_id="O3" value="17"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17.11" lower_limit="1.00" upper_limit="19.79"/>
                    <measurement group_id="O2" value="17.81" lower_limit="14.92" upper_limit="20.27"/>
                    <measurement group_id="O3" value="16.05" lower_limit="11.25" upper_limit="19.85"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>sCD40L D85</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="3"/>
                    <count group_id="O2" value="14"/>
                    <count group_id="O3" value="15"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.33" lower_limit="1.40" upper_limit="18.35"/>
                    <measurement group_id="O2" value="17.54" lower_limit="9.77" upper_limit="20.32"/>
                    <measurement group_id="O3" value="17.90" lower_limit="14.03" upper_limit="21.75"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Changes in the Ratio of Serums Soluble CD27 (sCD27):Soluble CD40 Ligand (sCD40L)</title>
        <description>Serum levels of sCD27, sCD40L, and the ratio of sCD27:sCD40L were determined by enzyme-linked immunosorbent assay (ELISA) pre and post vaccination. Changes in levels of serum cytokines and soluble factors was a descriptive result with median and interquartile range reported. No formal statistical analysis by dose level was performed given the small sample size.</description>
        <time_frame>Pre (Baseline), and approximately D29 (Post 1 vaccination), and D85 (post 3 vaccinations)</time_frame>
        <population>Sufficient serum was available before and after vaccination from 36 of 38 patients to analyze serum cytokines and soluble factors.</population>
        <group_list>
          <group group_id="O1">
            <title>Dose Level 1 - 1 Injection - Total Dose 2 x 10^8 IU</title>
            <description>Participants received Modified Vaccinia Ankara (MVA)-brachyury-modified vaccinia Ankara (MVA)-brachyury-B7-1, ICAM-1 (Intercellular Adhesion Molecule 1), and LFA-3 (lymphocyte function-associated antigen 3) TRICOM vaccine administered subcutaneously as 1 injection (I injection = 2 x 10^8 IU) of study drug at monthly (28 days +/- 4 days) intervals for 3 months. Patients with stable disease may continue to receive vaccine for up to 6 monthly doses.</description>
          </group>
          <group group_id="O2">
            <title>Dose Level 2 - 2 Injections - Total Dose 4 x 10^8 IU</title>
            <description>Participants received Modified Vaccinia Ankara (MVA)-brachyury-modified vaccinia Ankara (MVA)-brachyury-B7-1, ICAM-1 (Intercellular Adhesion Molecule 1), and LFA-3 (lymphocyte function-associated antigen 3) TRICOM vaccine administered subcutaneously as 2 injections (I injection = 2 x 10^8 IU) of study drug at monthly (28 days +/- 4 days) intervals for 3 months. Patients with stable disease may continue to receive vaccine for up to 6 monthly doses.</description>
          </group>
          <group group_id="O3">
            <title>Dose Level 3 - 4 Injections - Total Dose 8 x 10^8 IU</title>
            <description>Participants received Modified Vaccinia Ankara (MVA)-brachyury-modified vaccinia Ankara (MVA)-brachyury-B7-1, ICAM-1 (Intercellular Adhesion Molecule 1), and LFA-3 (lymphocyte function-associated antigen 3) TRICOM vaccine administered subcutaneously as 4 injections (I injection = 2 x 10^8 IU) of study drug at monthly (28 days +/- 4 days) intervals for 3 months. Patients with stable disease may continue to receive vaccine for up to 6 monthly doses.</description>
          </group>
        </group_list>
        <measure>
          <title>Changes in the Ratio of Serums Soluble CD27 (sCD27):Soluble CD40 Ligand (sCD40L)</title>
          <description>Serum levels of sCD27, sCD40L, and the ratio of sCD27:sCD40L were determined by enzyme-linked immunosorbent assay (ELISA) pre and post vaccination. Changes in levels of serum cytokines and soluble factors was a descriptive result with median and interquartile range reported. No formal statistical analysis by dose level was performed given the small sample size.</description>
          <population>Sufficient serum was available before and after vaccination from 36 of 38 patients to analyze serum cytokines and soluble factors.</population>
          <units>Ratio</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3"/>
                <count group_id="O2" value="16"/>
                <count group_id="O3" value="17"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>sCD27:sCD40L Pre</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="3"/>
                    <count group_id="O2" value="16"/>
                    <count group_id="O3" value="17"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.31" lower_limit="0.06" upper_limit="33.06"/>
                    <measurement group_id="O2" value="1.02" lower_limit="0.56" upper_limit="1.94"/>
                    <measurement group_id="O3" value="0.64" lower_limit="0.35" upper_limit="1.28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>sCD27:sCD40L D29</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="3"/>
                    <count group_id="O2" value="16"/>
                    <count group_id="O3" value="17"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.50" lower_limit="0.82" upper_limit="47.38"/>
                    <measurement group_id="O2" value="1.25" lower_limit="0.42" upper_limit="2.06"/>
                    <measurement group_id="O3" value="0.82" lower_limit="0.59" upper_limit="2.13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>sCD27:sCD40L D85</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="3"/>
                    <count group_id="O2" value="14"/>
                    <count group_id="O3" value="15"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.84" lower_limit="1.22" upper_limit="17.28"/>
                    <measurement group_id="O2" value="1.05" lower_limit="0.53" upper_limit="2.71"/>
                    <measurement group_id="O3" value="0.89" lower_limit="0.69" upper_limit="1.47"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Changes in Serum Cytokines Interleukin 2 (IL2), Interleukin 4 (IL4), Interleukin 10 (IL10), and Interferon Gamma (IFNg)</title>
        <description>Serum levels of IL-2, IL-4, IL-10, and IFNg were determined by enzyme-linked immunosorbent assay (ELISA) pre and post vaccination. Changes in levels of serum cytokines and soluble factors was a descriptive result with median and interquartile range reported. No formal statistical analysis by dose level was performed given the small sample size.</description>
        <time_frame>Pre (Baseline), and approximately D29 (Post 1 vaccination), and D85 (post 3 vaccinations)</time_frame>
        <population>Sufficient serum was available before and after vaccination from 36 of 38 patients to analyze serum cytokines and soluble factors.</population>
        <group_list>
          <group group_id="O1">
            <title>Dose Level 1 - 1 Injection - Total Dose 2 x 10^8 IU</title>
            <description>Participants received Modified Vaccinia Ankara (MVA)-brachyury-modified vaccinia Ankara (MVA)-brachyury-B7-1, ICAM-1 (Intercellular Adhesion Molecule 1), and LFA-3 (lymphocyte function-associated antigen 3) TRICOM vaccine administered subcutaneously as 1 injection (I injection = 2 x 10^8 IU) of study drug at monthly (28 days +/- 4 days) intervals for 3 months. Patients with stable disease may continue to receive vaccine for up to 6 monthly doses.</description>
          </group>
          <group group_id="O2">
            <title>Dose Level 2 - 2 Injections - Total Dose 4 x 10^8 IU</title>
            <description>Participants received Modified Vaccinia Ankara (MVA)-brachyury-modified vaccinia Ankara (MVA)-brachyury-B7-1, ICAM-1 (Intercellular Adhesion Molecule 1), and LFA-3 (lymphocyte function-associated antigen 3) TRICOM vaccine administered subcutaneously as 2 injections (I injection = 2 x 10^8 IU) of study drug at monthly (28 days +/- 4 days) intervals for 3 months. Patients with stable disease may continue to receive vaccine for up to 6 monthly doses.</description>
          </group>
          <group group_id="O3">
            <title>Dose Level 3 - 4 Injections - Total Dose 8 x 10^8 IU</title>
            <description>Participants received Modified Vaccinia Ankara (MVA)-brachyury-modified vaccinia Ankara (MVA)-brachyury-B7-1, ICAM-1 (Intercellular Adhesion Molecule 1), and LFA-3 (lymphocyte function-associated antigen 3) TRICOM vaccine administered subcutaneously as 4 injections (I injection = 2 x 10^8 IU) of study drug at monthly (28 days +/- 4 days) intervals for 3 months. Patients with stable disease may continue to receive vaccine for up to 6 monthly doses.</description>
          </group>
        </group_list>
        <measure>
          <title>Changes in Serum Cytokines Interleukin 2 (IL2), Interleukin 4 (IL4), Interleukin 10 (IL10), and Interferon Gamma (IFNg)</title>
          <description>Serum levels of IL-2, IL-4, IL-10, and IFNg were determined by enzyme-linked immunosorbent assay (ELISA) pre and post vaccination. Changes in levels of serum cytokines and soluble factors was a descriptive result with median and interquartile range reported. No formal statistical analysis by dose level was performed given the small sample size.</description>
          <population>Sufficient serum was available before and after vaccination from 36 of 38 patients to analyze serum cytokines and soluble factors.</population>
          <units>pg/mL</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3"/>
                <count group_id="O2" value="16"/>
                <count group_id="O3" value="17"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>IL-2 Pre</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="3"/>
                    <count group_id="O2" value="16"/>
                    <count group_id="O3" value="17"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.00" lower_limit="0.00" upper_limit="0.00"/>
                    <measurement group_id="O2" value="0.00" lower_limit="0.00" upper_limit="0.00"/>
                    <measurement group_id="O3" value="0.00" lower_limit="0.00" upper_limit="0.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>IL-2 D29</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="3"/>
                    <count group_id="O2" value="16"/>
                    <count group_id="O3" value="17"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.00" lower_limit="0.00" upper_limit="0.00"/>
                    <measurement group_id="O2" value="0.00" lower_limit="0.00" upper_limit="0.00"/>
                    <measurement group_id="O3" value="0.00" lower_limit="0.00" upper_limit="0.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>IL-2 D85</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="3"/>
                    <count group_id="O2" value="14"/>
                    <count group_id="O3" value="15"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.00" lower_limit="0.00" upper_limit="0.00"/>
                    <measurement group_id="O2" value="0.00" lower_limit="0.00" upper_limit="0.00"/>
                    <measurement group_id="O3" value="0.00" lower_limit="0.00" upper_limit="0.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>IL-10 Pre</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="3"/>
                    <count group_id="O2" value="16"/>
                    <count group_id="O3" value="17"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.00" lower_limit="0.00" upper_limit="0.00"/>
                    <measurement group_id="O2" value="0.00" lower_limit="0.00" upper_limit="0.00"/>
                    <measurement group_id="O3" value="0.00" lower_limit="0.00" upper_limit="0.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>IL-10 D29</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="3"/>
                    <count group_id="O2" value="16"/>
                    <count group_id="O3" value="17"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.00" lower_limit="0.00" upper_limit="0.00"/>
                    <measurement group_id="O2" value="0.00" lower_limit="0.00" upper_limit="0.00"/>
                    <measurement group_id="O3" value="0.00" lower_limit="0.00" upper_limit="0.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>IL-10 D85</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="3"/>
                    <count group_id="O2" value="14"/>
                    <count group_id="O3" value="15"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.00" lower_limit="0.00" upper_limit="0.00"/>
                    <measurement group_id="O2" value="0.00" lower_limit="0.00" upper_limit="0.00"/>
                    <measurement group_id="O3" value="0.00" lower_limit="0.00" upper_limit="0.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>IL-4 Pre</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="3"/>
                    <count group_id="O2" value="16"/>
                    <count group_id="O3" value="17"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.00" lower_limit="0.00" upper_limit="0.00"/>
                    <measurement group_id="O2" value="0.00" lower_limit="0.00" upper_limit="0.00"/>
                    <measurement group_id="O3" value="0.00" lower_limit="0.00" upper_limit="0.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>IL-4 D29</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="3"/>
                    <count group_id="O2" value="16"/>
                    <count group_id="O3" value="17"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.00" lower_limit="0.00" upper_limit="0.00"/>
                    <measurement group_id="O2" value="0.00" lower_limit="0.00" upper_limit="0.00"/>
                    <measurement group_id="O3" value="0.00" lower_limit="0.00" upper_limit="0.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>IL-4 D85</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="3"/>
                    <count group_id="O2" value="14"/>
                    <count group_id="O3" value="15"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.00" lower_limit="0.00" upper_limit="0.00"/>
                    <measurement group_id="O2" value="0.00" lower_limit="0.00" upper_limit="0.00"/>
                    <measurement group_id="O3" value="0.00" lower_limit="0.00" upper_limit="0.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>IFNg Pre</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="3"/>
                    <count group_id="O2" value="14"/>
                    <count group_id="O3" value="15"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.42" lower_limit="0.00" upper_limit="26.11"/>
                    <measurement group_id="O2" value="0.16" lower_limit="0.06" upper_limit="1.42"/>
                    <measurement group_id="O3" value="1.23" lower_limit="0.00" upper_limit="94.87"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>IFNg D29</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="3"/>
                    <count group_id="O2" value="16"/>
                    <count group_id="O3" value="17"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.23" lower_limit="0.00" upper_limit="31.59"/>
                    <measurement group_id="O2" value="0.84" lower_limit="0.26" upper_limit="2.17"/>
                    <measurement group_id="O3" value="0.74" lower_limit="0.00" upper_limit="131.90"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>IFNg D85</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="3"/>
                    <count group_id="O2" value="14"/>
                    <count group_id="O3" value="15"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.13" lower_limit="0.16" upper_limit="28.90"/>
                    <measurement group_id="O2" value="0.55" lower_limit="0.26" upper_limit="2.10"/>
                    <measurement group_id="O3" value="1.62" lower_limit="0.00" upper_limit="130.20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Correlation of Brachyury Expression in Tissue Samples With Clinical Outcomes.</title>
        <description>Correlation of brachyury expression in tissue samples with clinical outcomes.</description>
        <time_frame>2 -3 years</time_frame>
        <population>Tissue collection was optional and insufficient tissue was obtained to perform this analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Dose Level 1 - 1 Injection - Total Dose 2 x 10^8 IU</title>
            <description>Participants received Modified Vaccinia Ankara (MVA)-brachyury-TRICOM vaccine administered subcutaneously as 1 injection (I injection = 2 x 10^8 IU) of study drug at monthly (28 days +/- 4 days) intervals for 3 months. Patients with stable disease may continue to receive vaccine for up to 6 monthly doses.</description>
          </group>
          <group group_id="O2">
            <title>Dose Level 2 - 2 Injections - Total Dose 4 x 10^8 IU</title>
            <description>Participants received Modified Vaccinia Ankara (MVA)-brachyury-TRICOM vaccine administered subcutaneously as 2 injections (I injection = 2 x 10^8 IU) of study drug at monthly (28 days +/- 4 days) intervals for 3 months. Patients with stable disease may continue to receive vaccine for up to 6 monthly doses.</description>
          </group>
          <group group_id="O3">
            <title>Dose Level 3 - 4 Injections - Total Dose 8 x 10^8 IU</title>
            <description>Participants received Modified Vaccinia Ankara (MVA)-brachyury-TRICOM vaccine administered subcutaneously as 4 injections (I injection = 2 x 10^8 IU) of study drug at monthly (28 days +/- 4 days) intervals for 3 months. Patients with stable disease may continue to receive vaccine for up to 6 monthly doses.</description>
          </group>
        </group_list>
        <measure>
          <title>Correlation of Brachyury Expression in Tissue Samples With Clinical Outcomes.</title>
          <description>Correlation of brachyury expression in tissue samples with clinical outcomes.</description>
          <population>Tissue collection was optional and insufficient tissue was obtained to perform this analysis.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
                <count group_id="O3" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Date treatment consent signed to date off study, approximately 9 months and 6 days for DL1, 17 months and 3 days for DL2, and 23 months and 13 days for DL3.</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Dose Level 1 - 1 Injection - Total Dose 2 x 10^8 IU</title>
          <description>Participants received Modified Vaccinia Ankara (MVA)-brachyury-B7-1, ICAM-1 (Intercellular Adhesion Molecule 1), and LFA-3 (lymphocyte function-associated antigen 3) TRICOM vaccine administered subcutaneously as 1 injection (I injection = 2 x 10^8 IU) of study drug at monthly (28 days +/- 4 days) intervals for 3 months. Patients with stable disease may continue to receive vaccine for up to 6 monthly doses.</description>
        </group>
        <group group_id="E2">
          <title>Dose Level 2 - 2 Injections - Total Dose 4 x 10^8 IU</title>
          <description>Participants received Modified Vaccinia Ankara (MVA)-brachyury-B7-1, ICAM-1 (Intercellular Adhesion Molecule 1), and LFA-3 (lymphocyte function-associated antigen 3) TRICOM vaccine administered subcutaneously as 2 injections (I injection = 2 x 10^8 IU) of study drug at monthly (28 days +/- 4 days) intervals for 3 months. Patients with stable disease may continue to receive vaccine for up to 6 monthly doses.</description>
        </group>
        <group group_id="E3">
          <title>Dose Level 3 - 4 Injections - Total Dose 8 x 10^8 IU</title>
          <description>Participants received Modified Vaccinia Ankara (MVA)-brachyury-B7-1, ICAM-1 (Intercellular Adhesion Molecule 1), and LFA-3 (lymphocyte function-associated antigen 3) TRICOM vaccine administered subcutaneously as 4 injections (I injection = 2 x 10^8 IU) of study drug at monthly (28 days +/- 4 days) intervals for 3 months. Patients with stable disease may continue to receive vaccine for up to 6 monthly doses.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>CTCAE (4.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="17"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Colonic obstruction</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Colitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Lung infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Sepsis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Hip fracture</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Hyponatremia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>CTCAE (4.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="14" subjects_at_risk="17"/>
                <counts group_id="E3" subjects_affected="17" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Blood and lymphatic system disorders - Other, elevated neutrophil count</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Atrial fibrillation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Hypothyroidism</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Blurred vision</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Optic nerve disorder</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Dysphagia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Gastrointestinal disorders - Other, loss of appetite</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Injection site reaction</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="3"/>
                <counts group_id="E2" events="21" subjects_affected="13" subjects_at_risk="17"/>
                <counts group_id="E3" events="34" subjects_affected="15" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Edema limbs</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="3"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Fever</sub_title>
                <counts group_id="E1" events="4" subjects_affected="2" subjects_at_risk="3"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E3" events="7" subjects_affected="6" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Flu like symptoms</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="3"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E3" events="20" subjects_affected="12" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Laryngitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Nail infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Upper respiratory infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Bruising</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Creatinine increased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="17"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Alanine aminotransferase increased</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="3"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Alkaline phosphatase increased</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="3"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Blood bilirubin increased</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="3"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Lymphocyte count decreased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Platelet count decreased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Aspartate aminotransferase increased</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="3"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Neutrophil count decreased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>White blood cell decreased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Anorexia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Hypercalcemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Hyperkalemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Hypermagnesemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Hypokalemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Hypernatremia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Hyponatremia</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="3"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Non-cardiac chest pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Pain in extremity</sub_title>
                <counts group_id="E1" events="5" subjects_affected="2" subjects_at_risk="3"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="3"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Confusion</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Vaginal hemorrhage</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" events="4" subjects_affected="3" subjects_at_risk="3"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Dyspnea</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="3"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Epistaxis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Laryngeal hemorrhage</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Rash acneiform</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Pruritus</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hot flashes</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. James Gulley</name_or_title>
      <organization>National Cancer Institute</organization>
      <phone>301-480-8870</phone>
      <email>James_Gulley@nih.gov</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

